Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants

Molnupiravir is an orally administered, small‐molecule ribonucleoside prodrug of β‐D‐N4‐hydroxycytidine (NHC) that has demonstrated potent, broad‐spectrum preclinical activity against RNA viruses and has a high barrier to the development of resistance. A double‐blind, placebo‐controlled, phase I tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwamoto, Marian, Duncan, Kelly E., Wickremasingha, Prachi K., Zhao, Tian, Liberti, Maria V., Lemoine, Lieselotte, Decaesteker, Tatjana, Rottey, Sylvie, Maas, Brian M., Gillespie, Gillian, Stoch, S. Aubrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582664/
https://www.ncbi.nlm.nih.gov/pubmed/37526305
http://dx.doi.org/10.1111/cts.13602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582664/
https://www.ncbi.nlm.nih.gov/pubmed/37526305
http://dx.doi.org/10.1111/cts.13602

Ejemplares similares